Clinical Trial Update: RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for RD13-02 cell injection in patients with relapsed or refractory CD7-positive natural killer/T-cell lymphoma; currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Natural Killer T-cell Lymphoma

Drugs mentioned

• RD13-02

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: NK T-Cell Lymphoma, CART Therapy | Phase 1 | Status: RECRUITING